Danna Jennings

4PUBLICATIONS
72CO-AUTHORS
Molecular targetsNeurology and neuromuscular diseasesClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Dec 13, 2025
LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.

Anthony E Lang, Robert A Hauser, Lorraine V Kalia

|Sep 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.

Tien Dam, Gennaro Pagano, Michael C Brumm

|Feb 22, 2023
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.

Danna Jennings, Sarah Huntwork-Rodriguez, Maurits F J M Vissers

|Jun 08, 2022
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.

Danna Jennings, Sarah Huntwork-Rodriguez, Anastasia G Henry

Pageof 1